Efficacy of Sofosbuvir/Ledipasvir in Adolescents With Chronic Hepatitis C Genotypes 1, 3, and 4: A Real-world Study

Daniele Serranti, Gabriella Nebbia, Mara Cananzi, Emanuele Nicastro, Fabiola Di Dato, Federica Nuti, Silvia Garazzino, Erika Silvestro, Vania Giacomet, Federica Forlanini, Michele Pinon, Pier Luigi Calvo, Silvia Riva, Icilio Dodi, Antonina Marta Cangelosi, Roberto Antonucci, Silvia Ricci, Elisa Bartolini, Greta Mastrangelo, Sandra TrapaniMatteo Lenge, Paola Gaio, Pietro Vajro, Raffaele Iorio, Lorenzo D'Antiga, Giuseppe Indolfi

Research output: Contribution to journalArticlepeer-review

Abstract

OBJECTIVES: Sofosbuvir/Ledipasvir (SOF/LDV) has been approved by the European Medicine Agency (EMA) for the treatment of children and adolescents (at least 3 years of age) with chronic hepatitis C (CHC) genotype 1, 3, and 4 infection. The aim of this study was to evaluate the efficacy and safety of SOF/LDV in adolescents (12 to
Original languageEnglish
Pages (from-to)95-100
Number of pages6
JournalJournal of Pediatric Gastroenterology and Nutrition
Volume72
Issue number1
DOIs
Publication statusAccepted/In press - Jul 29 2020

Fingerprint Dive into the research topics of 'Efficacy of Sofosbuvir/Ledipasvir in Adolescents With Chronic Hepatitis C Genotypes 1, 3, and 4: A Real-world Study'. Together they form a unique fingerprint.

Cite this